Published 10 days ago • loading... • Updated 10 days ago

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

On Thursday, Rigel Pharmaceuticals, Inc. announced final Phase 3 AcceleRET-Lung trial data for GAVRETO and real-world outcomes for REZLIDHIA will be presented at the 2026 ASCO Annual Meeting and EHA2026 Congress.
Rigel will present the Phase 3 AcceleRET-Lung study demonstrating GAVRETO's primary progression-free survival endpoint in RET fusion-positive NSCLC, alongside new real-world data for REZLIDHIA in relapsed or refractory AML.
Data includes a 60.8% CR/CRh rate for REZLIDHIA and an estimated 74% 48-month overall survival for GAVRETO. "Together, these data reinforce our ability to deliver targeted therapies," Rigel CEO Raul Rodriguez said.
Safety profiles remain a focus, with infections occurring in 72% of GAVRETO-treated patients during the AcceleRET-Lung trial and 23% of REZLIDHIA patients experiencing hepatotoxicity including grade 3 or 4 events.
Investors are monitoring how these results translate into label evolution and real-world clinical adoption, particularly regarding management of infection and hepatotoxicity signals in broader patient populations.

Insights by Ground AI

26 Articles

Bennington Banner

+25 Reposted by 25 other sources

Center

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLCFinal analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in…

10 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year